Cover Image
市場調查報告書

血管再阻塞:開發中產品分析

Restenosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213108
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
血管再阻塞:開發中產品分析 Restenosis - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 48 Pages
簡介

血管再阻塞是指血流受限,血管再堵塞。症狀有呼吸急促、步行困難、胸部疼痛等症狀。危險因素有年齡,性別,家族病史或人種,糖尿病。治療方法包含外科手術,血栓溶解療法等。

本報告提供血管再阻塞的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

血管再阻塞概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • advanceCor GmbH
  • Bio3 Research S.r.l
  • CSPC Pharmaceutical Group Limited
  • CytoTools AG
  • Shire Plc
  • XBiotech USA, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Annexin A-5
  • butylphthalide
  • COR-3
  • CT-406
  • CV-18C3
  • Didox
  • HMW-02A
  • HMW-02Ap
  • HO-3867
  • PVS-10200
  • Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury
  • VAN 10-4

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8389IDB

Summary

Global Markets Direct's, 'Restenosis - Pipeline Review, H2 2016', provides an overview of the Restenosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Restenosis
  • The report reviews pipeline therapeutics for Restenosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Restenosis therapeutics and enlists all their major and minor projects
  • The report assesses Restenosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Restenosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Restenosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Restenosis Overview
  • Therapeutics Development
    • Pipeline Products for Restenosis - Overview
    • Pipeline Products for Restenosis - Comparative Analysis
  • Restenosis - Therapeutics under Development by Companies
  • Restenosis - Therapeutics under Investigation by Universities/Institutes
  • Restenosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Restenosis - Products under Development by Companies
  • Restenosis - Products under Investigation by Universities/Institutes
  • Restenosis - Companies Involved in Therapeutics Development
    • Bio3 Research S.r.l
    • CytoTools AG
    • XBiotech Inc
  • Restenosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (connective tissue growth factor + insulin human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alendronate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-18C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • didox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMW-02Ak - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMW-02Ap - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HO-3867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TW-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Restenosis - Dormant Projects
  • Restenosis - Discontinued Products
  • Restenosis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis
      • Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease
      • Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites
      • Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Restenosis, H2 2016
  • Number of Products under Development for Restenosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Restenosis - Pipeline by Bio3 Research S.r.l, H2 2016
  • Restenosis - Pipeline by CytoTools AG, H2 2016
  • Restenosis - Pipeline by XBiotech Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Restenosis - Dormant Projects, H2 2016
  • Restenosis - Dormant Projects (Contd..1), H2 2016
  • Restenosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Restenosis, H2 2016
  • Number of Products under Development for Restenosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top